Envoy Medical (COCH) awards 250K options to Potashnick
Rhea-AI Filing Summary
Envoy Medical, Inc. (COCH) reported that officer Robert Potashnick, CAO & VP of Finance, received a grant of 250,000 stock options on 2026-08-24 with an exercise price of $0.746 per share, expiring on 2036-08-24. According to the vesting terms, options to purchase 62,500 shares vest on 2027-08-24 and the remaining 187,500 shares vest pro rata on the 24th of each month thereafter for 36 months.
Potashnick also has an existing option covering 15,000 underlying shares at a $0.53 exercise price, plus direct holdings of 212,500 shares of Class A common stock. In addition, he holds warrants exercisable for 127,500 and 212,500 Class A shares at a $0.40 exercise price, which become exercisable upon shareholder approval and have expirations tied to key FDA milestones for Envoy Medical’s Acclaim CI Device.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Potashnick Robert
Role
CAO & VP of Finance
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F2 | 250,000 | $0.00 | $0.00 |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Warrant (right to buy) F3, F4 | -- | -- | -- |
| holding | Warrant (right to buy) F3, F5 | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 265,000 shares (Direct);
Warrant (right to buy) — 340,000 shares (Direct);
Class A Common Stock — 212,500 shares (Direct)
Footnotes (5)
- F1. Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.
- F2. Options to purchase 62,500 shares vest on 8/24/2027, and 187,500 shares vest pro rata on the 24th of each month thereafter for 36 consecutive months.
- F3. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
- F4. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
- F5. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.
Key Figures
New stock option grant underlying shares: 250,000 shares of Class A Common Stock
New option exercise price: $0.746 per share
Initial vesting tranche of new options: 62,500 shares
+5 more
8 metrics
New stock option grant underlying shares
250,000 shares of Class A Common Stock
Options granted to Robert Potashnick on 2026-08-24
New option exercise price
$0.746 per share
Exercise price for 250,000-share option grant expiring 2036-08-24
Initial vesting tranche of new options
62,500 shares
Vest on 2027-08-24
Remainder vesting of new options
187,500 shares
Vest pro rata monthly over 36 months starting after 2027-08-24
Existing option underlying shares
15,000 shares
Existing stock option at $0.53 exercise price, expiring 2036-02-05
Existing option exercise price
$0.53 per share
Exercise price for 15,000-share option position
Common stock directly held
212,500 shares
Direct holdings of Envoy Medical Class A Common Stock
Warrant underlying shares and exercise price
127,500 and 212,500 shares at $0.40 per share
Warrants exercisable upon shareholder approval; expirations tied to FDA milestones
Key Terms
Premarket Approval Application, Acclaim CI Device, Series A-1 Warrants, Series A-2 Warrants, +1 more
5 terms
Premarket Approval Application medical
"submits a Premarket Approval Application to the Food and Drug Administration"
A premarket approval application is a formal, data-packed request submitted to regulators to get permission to sell a high-risk medical device. It is like asking for a driver’s license for a complex product: the company must show clinical trial results, safety testing and manufacturing controls to prove the device works and won’t harm people. Investors watch these filings because approval unlocks revenue and sharply reduces the regulatory risk that can halt a product’s commercial launch.
Acclaim CI Device medical
"its Acclaim CI Device"
Series A-1 Warrants financial
"The Series A-1 Warrants expire on the earlier of"
Series A-1 warrants are tradable instruments that give their holder the right, but not the obligation, to buy a company’s shares at a preset price for a limited time; they are typically issued alongside a specific financing round labeled “Series A-1.” Think of them like a coupon that lets an investor buy stock at a locked-in price later — if the company’s share price rises above that price the coupon becomes valuable, otherwise it may expire worthless. For investors they matter because exercising warrants can increase potential upside while also diluting existing shareholders and affecting future ownership percentages and share value.
Series A-2 Warrants financial
"The Series A-2 Warrants expire on the earlier of"
Series A-2 warrants are a specific class of long‑term options issued by a company that give the holder the right to buy a set number of shares at a pre‑agreed price. Think of them as a coupon for future stock purchases: they can add potential value for the holder if the share price rises, but they also represent potential dilution for existing shareholders and can affect an investor’s ownership and returns when exercised or converted.
Class A Common Stock financial
"shares of Class A Common Stock underlying the warrants"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
What did COCH officer Robert Potashnick receive in this Form 4 filing?
He received a grant of 250,000 stock options for Envoy Medical, Inc. Class A Common Stock on 2026-08-24, with an exercise price of $0.746 per share and an expiration date of 2036-08-24, as compensation in the form of equity awards.
What are the vesting terms of the new 250,000 COCH stock options?
Options to purchase 62,500 shares vest on 2027-08-24. The remaining 187,500 shares vest pro rata on the 24th of each month for 36 consecutive months thereafter, as disclosed in the vesting footnote.
What other stock options does Robert Potashnick hold in COCH?
He holds an existing stock option with an exercise price of $0.53 per share covering 15,000 underlying shares of Envoy Medical Class A Common Stock, with an expiration date of 2036-02-05. The vesting for these options is staged over several years.
Are the COCH warrants held by Robert Potashnick linked to FDA milestones?
Yes. The Series A-1 Warrants expire the earlier of two years from their initial exercise date or 30 days after Envoy Medical announces submission of a Premarket Approval Application for its Acclaim CI Device. The Series A-2 Warrants have a similar structure tied to FDA approval.
AI-generated analysis. How Rhea-AI works. Not financial advice.
